Latest period
$995.40M
YoY change
+1.1%
5Y CAGR
+18.1%
Peak year (2025)
$993.70M
Latest annual
$993.70M
Stock-Based Compensation history chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
Latest: $993.70M
Stock-Based Compensation growth chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
Latest: +1.1%
Stock-Based Compensation history table for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
| 2025 | $993.70M | +1.1% | +$10.90M | ||
| 2024 | $982.80M | +11.1% | +$97.80M | ||
| 2023 | $885.00M | +22.1% | +$160.00M | ||
| 2022 | $725.00M | +20.5% | +$123.30M | ||
| 2021 | $601.70M | +39.3% | +$169.70M | ||
| 2020 | $432.00M | -7.0% | −$32.30M | ||
| 2019 | $464.30M | +8.6% | +$36.90M | ||
| 2018 | $427.40M | -15.7% | −$79.88M | ||
| 2017 | $507.28M | -9.4% | −$52.60M | ||
| 2016 | $559.88M | +22.0% | +$100.83M | ||
| 2015 | $459.05M | +49.4% | +$151.81M | ||
| 2014 | $307.24M | +54.9% | +$108.84M | ||
| 2013 | $198.40M | +110.7% | +$104.24M | ||
| 2012 | $94.16M | +67.9% | +$38.06M | ||
| 2011 | $56.09M | +40.6% | +$16.20M | ||
| 2010 | $39.90M | +27.6% | +$8.64M | ||
| 2009 | $31.26M | -3.9% | −$1.26M | ||
| 2008 | $32.52M | +15.8% | +$4.45M | ||
| 2007 | $28.07M | — | +$28.07M | ||
| 2006 | $0.00 | — | $0.00 | ||
| 2005 | $0.00 | — | $0.00 | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | $0.00 | ||
| 2002 | $0.00 | — | $0.00 | ||
| 2001 | $0.00 | — | $0.00 | ||
| 2000 | $0.00 | — | $0.00 | ||
| 1999 | $0.00 | — | $0.00 | ||
| 1998 | $0.00 | — | $0.00 | ||
| 1997 | $0.00 | — | $0.00 | ||
| 1996 | $0.00 | — | $0.00 | ||
| 1995 | $0.00 | — | $0.00 | ||
| 1994 | $0.00 | — | $0.00 | ||
| 1993 | $0.00 | — | $0.00 | ||
| 1992 | $0.00 | — | $0.00 | ||
| 1991 | $0.00 | — | — |
- 2025$993.70M+1.1%
- 2024$982.80M+11.1%
- 2023$885.00M+22.1%
- 2022$725.00M+20.5%
- 2021$601.70M+39.3%
- 2020$432.00M-7.0%
- 2019$464.30M+8.6%
- 2018$427.40M-15.7%
- 2017$507.28M-9.4%
- 2016$559.88M+22.0%
- 2015$459.05M+49.4%
- 2014$307.24M+54.9%
- 2013$198.40M+110.7%
- 2012$94.16M+67.9%
- 2011$56.09M+40.6%
- 2010$39.90M+27.6%
- 2009$31.26M-3.9%
- 2008$32.52M+15.8%
- 2007$28.07M—
- 2006$0.00—
- 2005$0.00—
- 2004$0.00—
- 2003$0.00—
- 2002$0.00—
- 2001$0.00—
- 2000$0.00—
- 1999$0.00—
- 1998$0.00—
- 1997$0.00—
- 1996$0.00—
- 1995$0.00—
- 1994$0.00—
- 1993$0.00—
- 1992$0.00—
- 1991$0.00—
Stock-Based Compensation values are taken from Regeneron Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Regeneron Pharmaceuticals (REGN)
Stock-Based Compensation for Regeneron Pharmaceuticals (REGN): headline value $995.40M · YoY +1.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Regeneron Pharmaceuticals (REGN) stock-based compensation is $993.70M – edged up 1.1% year-over-year.
Regeneron Pharmaceuticals stock-based compensation has grown on net over the period, with a +18.1% compound annual growth rate over 2020–2025 (5 years).
The record annual stock-based compensation stands at $993.70M, reached in 2025; the historical low of $0.00 was recorded in 1991.
Regeneron Pharmaceuticals Stock-Based Compensation by Year
Regeneron Pharmaceuticals Stock-Based Compensation 2025: $993.70M
2025's stock-based compensation for Regeneron Pharmaceuticals came in at $993.70M, edged up 1.1% from 2024. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Stock-Based Compensation 2024: $982.80M
Regeneron Pharmaceuticals posted stock-based compensation of $982.80M in 2024, grew 11.1% from 2023.
Regeneron Pharmaceuticals Stock-Based Compensation 2023: $885.00M
In 2023, Regeneron Pharmaceuticals reported stock-based compensation of $885.00M, grew 22.1% from 2022.
Regeneron Pharmaceuticals Stock-Based Compensation 2022: $725.00M
Regeneron Pharmaceuticals stock-based compensation in 2022 was $725.00M, grew 20.5% from 2021.
Regeneron Pharmaceuticals Stock-Based Compensation 2021: $601.70M
Regeneron Pharmaceuticals stock-based compensation in 2021 was $601.70M.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by Stock-Based Compensation
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation